See more : G City Ltd (GCT.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Evgen Pharma plc (EVG.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evgen Pharma plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Blue Foundry Bancorp (BLFY) Income Statement Analysis – Financial Results
- Biocon Limited (BIOCON.NS) Income Statement Analysis – Financial Results
- Apollo Tyres Limited (APOLLOTYRE.NS) Income Statement Analysis – Financial Results
- VL E-Governance & IT Solutions Limited (VLEGOV.NS) Income Statement Analysis – Financial Results
- Erdene Resource Development Corporation (ERD.TO) Income Statement Analysis – Financial Results
Evgen Pharma plc (EVG.L)
About Evgen Pharma plc
Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 442.00K | 0.00 | 194.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 13.00K | 16.00K | 3.39M | 21.00K | 21.00K | 21.00K | 17.00K | 8.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 429.00K | -16.00K | -3.20M | -21.00K | -21.00K | -21.00K | -17.00K | -8.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 97.06% | 0.00% | -1,646.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.72M | 2.60M | 2.73M | 1.70M | 1.69M | 1.68M | 2.11M | 383.00K | 196.00K | 498.00K | 573.00K |
| General & Administrative | 765.00K | 0.00 | 635.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 14.00K | 0.00 | 18.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 779.00K | 576.00K | 653.00K | 1.43M | 1.41M | 3.03M | 3.66M | 1.75M | 951.00K | 378.00K | 343.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 755.00K | 459.00K | 388.00K |
| Operating Expenses | 5.50M | 3.18M | 3.38M | 3.13M | 3.10M | 3.03M | 3.66M | 2.43M | 951.00K | 957.00K | 961.00K |
| Cost & Expenses | 5.51M | 3.19M | 3.40M | 3.15M | 3.12M | 3.03M | 3.66M | 2.43M | 951.00K | 957.00K | 961.00K |
| Interest Income | 98.00K | 24.00K | 0.00 | 0.00 | 0.00 | 0.00 | 14.00K | 783.00K | 1.06M | 199.00K | 1.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 791.00K | 1.06M | 199.00K | 1.00K |
| Depreciation & Amortization | 13.00K | 16.00K | 18.00K | 21.00K | 21.00K | 21.00K | 17.00K | 8.00K | 7.00K | 8.00K | 5.00K |
| EBITDA | -5.06M | -3.18M | -3.19M | -3.13M | -3.10M | -3.01M | -3.63M | -2.02M | -944.00K | -949.00K | -942.00K |
| EBITDA Ratio | -1,144.12% | 0.00% | -1,642.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.07M | -3.19M | -3.20M | -3.15M | -3.12M | -3.03M | -3.66M | -1.75M | -1.25M | -957.00K | -947.00K |
| Operating Income Ratio | -1,147.06% | 0.00% | -1,651.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 64.00K | 22.00K | 0.00 | -20.00K | 0.00 | 0.00 | 14.00K | -1.47M | -1.35M | -199.00K | -1.00K |
| Income Before Tax | -5.01M | -3.17M | -3.21M | -3.17M | -3.12M | -3.03M | -3.64M | -3.22M | -2.30M | -1.16M | -948.00K |
| Income Before Tax Ratio | -1,132.58% | 0.00% | -1,656.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -963.00K | -439.00K | -539.00K | -451.00K | -496.00K | 443.00K | 576.00K | 85.00K | -30.00K | -79.00K | -82.00K |
| Net Income | -4.04M | -2.73M | -2.67M | -2.72M | -2.62M | -2.58M | -3.07M | -3.13M | -2.27M | -1.08M | -866.00K |
| Net Income Ratio | -914.71% | 0.00% | -1,378.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | -0.03 | -0.04 | -0.06 | -0.03 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | -0.03 | -0.04 | -0.06 | -0.03 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 274.89M | 274.89M | 147.02M | 131.23M | 97.28M | 78.70M | 73.15M | 49.79M | 73.95M | 73.95M | 73.95M |
| Weighted Avg Shares Out (Dil) | 274.89M | 274.89M | 147.02M | 131.23M | 97.28M | 78.70M | 73.15M | 49.80M | 73.95M | 73.95M | 73.95M |
Source: https://incomestatements.info
Category: Stock Reports